Where does SK Biopharmaceuticals Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), SK Biopharmaceuticals Co., Ltd. ranks #4,433 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does SK Biopharmaceuticals Co., Ltd. hold?

SK Biopharmaceuticals Co., Ltd. holds 80 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is SK Biopharmaceuticals Co., Ltd.'s Innovation Score?

SK Biopharmaceuticals Co., Ltd. has an Innovation Score of 40.0 out of 100 (top 37% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is SK Biopharmaceuticals Co., Ltd.'s patent grant rate increasing or decreasing?

SK Biopharmaceuticals Co., Ltd.'s recent grant velocity is -24% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for SK Biopharmaceuticals Co., Ltd.'s patents?

SK Biopharmaceuticals Co., Ltd.'s patents average 15.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the SK Biopharmaceuticals Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

SK Biopharmaceuticals Co., Ltd.

Q: What technology areas does SK Biopharmaceuticals Co., Ltd. focus on?

SK Biopharmaceuticals Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 78 patents. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 80 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, SK ranks #4,433 of 49,997 tracked US assignees by granted-patent volume, with 80 patents across 8 technology areas.

#4,433
of 49,997 US assignees by volume: Top 37%
by Innovation Score (40.0/100): 15.2
avg claims per patent: -24%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4433 · Foreign Corporation #4,433 · 80 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 80 grants
TOP-DECILE #4,433/49,997
PHOTO-FINISH Olympus Imaging
CPC-NARROW A61P · 8 areas
INNOV-PAR 40.0/100
CLAIMS-RICH 15.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -24% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Olympus Imaging Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Kerr · near

40
Nativo · near

40
Realnetworks · near

40
SK Biopharmaceuticals · this assignee

40
Ceva Sante Animale · near

40
3D Lighting… · lowest

7

What this shows SK's Innovation Score is 40.0/100 (top 37% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where SK's grants concentrate

SK Biopharmaceuticals Co., Ltd. is a focused PatentsView assignee: 8 CPC subclasses with 97.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (12 grants) versus a trough of 3 in 2020. By volume, SK sits between Olympus Imaging Corp. and Silk Road Medical, Inc..

SK's three-year grant acceleration

From 2019–2021 to 2022–2024, SK Biopharmaceuticals Co., Ltd. moved from 22 to 19 grants (0.86x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Olympus Imaging

80
Pratt Retail Spec…

80
Shenzhen BYD Auto…

80
Sila Nanotechnolo…

80
Soken

80
SPM Oil & Gas

80
Sumitomo Heavy In…

80
Silk Road Medical

80
SK Biopharmaceuti… ◀

80

What this shows SK holds 80 patents at rank #4,432, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near SK

By rank, the assignees closest to #4,432 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in SK's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for SK, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Realnetworks LLC 40 Kerr Corporation 40 Nativo, Inc. 40 Ceva Sante Animale 40

Similar claim depth

Nearest assignees by average claims per patent (15.2 here).

Perkins Engines Company Limited 15.2 avg BSN Medical GMBH 15.2 avg Basf Coatings GMBH 15.2 avg Doosan Heavy Industries & Construction Co., Ltd. 15.2 avg

SK's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 37% higher than 63% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

SK Biopharmaceuticals Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	5.0%
2016	10	12.5%
2017	12	15.0%
2018	7	8.8%
2019	9	11.3%
2020	3	3.8%
2021	10	12.5%
2022	5	6.3%
2023	9	11.3%
2024	5	6.3%
2025partial year	6	7.5%

Which technologies does SK Biopharmaceuticals Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 78

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 70

C07D - Heterocyclic Compounds 27

C07C - Acyclic OR Carbocyclic Compounds 26

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 3

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#4,433

of 49,997 tracked assignees

Innovation Score

40.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

SK Biopharmaceuticals Co., Ltd.'s patent record in context - here's where to go next.

SK Biopharmaceuticals Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 97.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,433 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare SK Biopharmaceuticals Co., Ltd. against Olympus Imaging Corp., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 40.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.